GLRA1

GLRA1 Full Name

glycine receptor, alpha 1

GLRA1 Introduction

GLRA1 encodes the α1 subunit of the inhibitory glycine receptor (GlyR), a pentameric ligand-gated chloride channel belonging to the Cys-loop superfamily. The mature receptor is predominantly expressed in the spinal cord and brainstem, where it assembles as heteromeric complexes composed of α1 and β subunits at postsynaptic densities. Structurally, the α1 subunit harbors an extracellular domain (ECD) responsible for glycine binding and a transmembrane domain (TMD) comprising four α-helices (TM1–TM4), with the TM2 helix lining the ion-conducting pore. Upon glycine binding, rapid chloride influx hyperpolarizes the postsynaptic membrane, thereby suppressing neuronal excitability. This glycinergic inhibitory tone is essential for the fine-tuned coordination of motor output, sensory gating, and pain processing in the central nervous system.

Figure 1. Structure and diversity of inhibitory ligand-gated ion channels. (Source: Moss SJ, et al. 2001)

Beyond its fundamental role in fast inhibitory neurotransmission, GLRA1 has been increasingly recognized as a modulator of nociceptive signaling. In the dorsal horn of the spinal cord, synaptic α1β GlyRs participate in a gate-control mechanism that limits the propagation of pain signals to supraspinal centers. An alternatively spliced variant of the α1 subunit, α1ins, harbors an intracellular domain insert whose serine residue (S380) can be phosphorylated downstream of ERK activation, triggering receptor ubiquitination and endocytic degradation. This process results in disinhibition of dorsal horn circuits and heightened pain sensitivity, a pathway that has been linked to chronic inflammatory pain states. Conversely, activation of adenosine A1 receptors reverses S380 phosphorylation via protein phosphatase-1, restoring glycinergic tone and providing analgesia. These findings place GLRA1 at the intersection of inhibitory neurotransmission and pain modulation.

The most established clinical consequence of GLRA1 dysfunction is hereditary hyperekplexia (HPX; also known as startle disease), a rare autosomal dominant or recessive neuromotor disorder. GLRA1 mutations account for approximately 80% of genetically confirmed HPX cases, with more than 77 distinct sequence variants catalogued to date. Clinically, affected individuals present with exaggerated non-habituating startle responses to sudden auditory, visual, or tactile stimuli, neonatal generalized hypertonia, and an episodic stiffening that can precipitate apnea or traumatic falls. Dominant variants predominantly cluster around the TM2 domain and extracellular Loop 2, impairing chloride conductance or glycine sensitivity through loss-of-function mechanisms. A minority of dominant mutations exhibit paradoxical gain-of-function, inducing spontaneous channel opening and aberrant cation influx. Recessive variants are more broadly distributed and typically cause reduced surface expression or complete absence of functional receptors. In addition to HPX, patients carrying GLRA1 mutations have been found to exhibit lower pain thresholds than healthy individuals, suggesting a broader contribution of impaired α1-GlyR function to sensory hypersensitivity. Treatment with benzodiazepines, which enhance GABA-gated chloride conductance, substantially alleviates startle episodes in most patients, though a glycine receptor-specific pharmacological strategy remains an unmet therapeutic goal.

Alternate Names for GLRA1

GLRA1; glycine receptor, alpha 1; GLYRA1; glycine receptor subunit alpha-1; glycine receptor 48 kDa subunit; glycine receptor, alpha 1 subunit; glycine receptor strychnine-binding subunit;

View more

• 1. Moss SJ, et al. Constructing inhibitory synapses. Nat Rev Neurosci. 2001 Apr;2(4):240-50.
  2. Zhan F, et al. Excessive Startle with Novel GLRA1 Mutations in 4 Chinese Patients and a Literature Review of GLRA1-Related Hyperekplexia. J Clin Neurol. 2020 Apr;16(2):230-236.